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Background-—The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2P), a 0-to-9-point
system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular
events (MACE) (a composite of cardiovascular death, recurrent myocardial infarction, or ischemic stroke) among patients with a
recent myocardial infarction. Its performance has not been examined internationally outside of a clinical trial setting.
Methods and Results-—We evaluated the performance of TRS2P for predicting MACE in 53 599 patients with recent myocardial
infarction in 5 international cohorts fromNew Zealand, South Korea, Sweden, and theUnited States participating in the Chronic Kidney
Disease Prognosis Consortium. Overall, there were 19 444 cases of MACE across 5 cohorts over amean follow-up of 5 years, and the
overall MACE rate ranged from 5.0 to 18.4 (per 100 person-years). The TRS2P showed modest calibration (Brier score ranged from
0.144 to 0.173) and discrimination (C-statistics >0.61 in all studies except 1 from Korea with 0.55) across cohorts relative to its
original Brier score of 0.098 and C-statistic of 0.67 in the derived data set. Although there was some heterogeneity across cohorts, the
9 predictors in the TRS2P were generally associated with higher MACE risk, with strongest associations observed (meta-analyzed
adjusted hazard ratio 1.6–1.7) for history of heart failure, age ≥75 years, and prior stroke, followed by peripheral artery disease,
kidney dysfunction, diabetes mellitus, and hypertension (hazard ratio 1.3–1.4). Prior coronary bypass graft surgery and smoking did
not reach statistical signiﬁcance (hazard ratio 1.1).
Conclusions-—TRS2P, a simple scoring system with 9 routine clinical factors, was modestly predictive of secondary events when
applied in patients with recent myocardial infarction from diverse clinical and geographic settings. ( J Am Heart Assoc. 2018;7:
e008426. DOI: 10.1161/JAHA.117.008426.)
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P atients with recent myocardial infarction (MI) are gener-ally at high risk of subsequent adverse events.1–5 Of
importance, a large risk variation is recognized among
patients with MI depending on demographics, comorbidities,
and severity of MI.6,7 Risk stratiﬁcation is important because
it may inﬂuence the selection of secondary preventive
therapy, such as intensive antiplatelet therapy where beneﬁt
may only outweigh harm in higher risk patients but not among
lower risk ones.8–10 In this context, the Thrombolysis in
Myocardial Infarction (TIMI) Study Group recently developed a
simple scoring system, the TIMI Risk Score for Secondary
Prevention (TRS2°P).10 This risk stratiﬁcation tool is for
classifying the risk of secondary outcomes among patients
with recent MI, using 9 clinical and behavioral factors readily
available in clinical practice. TRS2°P has been recently
validated outside of a clinical trial setting in 2 US regional
healthcare systems11 but not in other countries or regions.
External validation and replication in diverse real-world
settings should be requisite for implementation of the
algorithm in clinical practice. Therefore, we examined the
performance of TRS2°P for predicting major adverse cardio-
vascular events (MACEs) after recent MI in 5 cohorts (from
New Zealand, South Korea, Sweden, and the United States)
participating in an international consortium, the Chronic
Kidney Disease Prognosis Consortium (CKD-PC). To identify
potential explanations for varying performance of TRS2°P
across those 5 cohorts, we quantiﬁed the associations of
each predictor with MACEs as well.
Methods
Because of the data use agreement with participating cohorts
of the CKD-PC, the study data and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. However, it is
possible to obtain ARIC (Atherosclerosis Risk in Communities
Study) data from the National Heart, Lung, and Blood Institute
BioLINCC repository.12
Study Design and Participants
This study was performed as an ancillary study of CKD-PC. CKD-
PC currently consists of >11 million participants from >70
cohorts with detailed clinical and outcome data (eg, mortality
and end-stage renal disease) from >40 countries.13,14 For this
speciﬁc study, based on data collected as part of the CKD-PC,
we identiﬁed 5 studies with ≥1000 MI cases during follow-up
that could be linked to data on the 9 predictors of TRS2°P.
These 5 studies included the ARIC and the RCAV (Racial and
Cardiovascular Risk Anomalies in CKD Cohort) from the United
States, the SCREAM (Stockholm Creatinine Measurements
Cohort) fromSweden, the KHS (KoreanHeart Study) fromSouth
Korea, and the NZDCS (New Zealand Diabetes Cohort Study)
from New Zealand. A total of 53 599 patients with recent acute
MI who survived at least 2 weeks from index date of MI were
included in this study, to be in line with inclusion criteria of the
derived study population of TRA2°P (Thrombin Receptor
Antagonist in Secondary Prevention of Atherothrombotic
Ischemic Event)-TIMI50.10 Details of the study design and the
approach for identifying recent MI cases in each cohort are
summarized in Data S1 and S2. This study was approved as not
human subject research by the institutional Review Board at the
JohnsHopkins Bloomberg School of Public Health because of its
nature of pre-existing deidentiﬁed secondary data analysis.
Nine Predictors Used in TRS2°P
The following 9 predictors in TRS2°P were identiﬁed in each of the
5 studies (Data S1): heart failure (yes versus no), hypertension (yes
versus no), age (≥ versus <75 years), diabetesmellitus (yes versus
no), prior stroke (yes versus no), prior coronary artery bypass
grafting (CABG) (yes versus no), peripheral artery disease (yes
versus no), reducedkidney function (estimated glomerularﬁltration
rate < versus ≥60 mL/min per 1.73 m2), and current smoking
(yes versus no).10 We calculated estimated glomerular ﬁltration
rate using the creatinine equation from theChronic KidneyDisease
EpidemiologyCollaboration.15 Based on the presence and absence
of these 9 predictors, TRS2°P ranged from 0 to 9.
Outcomes
The primary outcome of interest was MACE, deﬁned by a
composite of cardiovascular death, recurrent MI, or ischemic
Clinical Perspective
What Is New?
• The Thrombolysis in Myocardial Infarction Risk Score for
Secondary Prevention, a simple scoring system with 9
routine clinical factors predicting adverse outcome after
recent myocardial infarction, is modestly predictive in
international settings with different demographic and clin-
ical characteristics.
What Are the Clinical Implications?
• The Thrombolysis in Myocardial Infarction Risk Score for
Secondary Prevention is useful to estimate the risk of
secondary events among patients with a recent myocardial
infarction in a broad range of clinical settings.
• Given its simple scoring system with routinely collected
variables, the Thrombolysis in Myocardial Infarction Risk
Score for Secondary Prevention will help healthcare
providers easily acknowledge the risk of patients based on
patients’ clinical conditions and guide risk-centered man-
agement in patients with recent myocardial infarction.
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stroke.10 Cardiovascular death was deﬁned as death caused
by MI, heart failure, stroke, or sudden cardiac death as the
primary cause. All-cause death was investigated in RCAV
since cause of death was not available. Patients were followed
until date of MACE, death, or the end of follow-up, whichever
came ﬁrst.
Statistical Analysis
Baseline characteristics of individuals with recent MI in each
study were summarized as mean and SD or median and
interquartile range for continuous variables and percentage
for categorical variables. Subsequently, we determined pre-
diction statistics in a 3-year time frame with ﬁne categories of
TRS2°P 0, 1, 2, 3, 4, 5, 6, and ≥7 as carried out in its derived
data set.10 As a measure of discrimination, we estimated
Harrell’s C-statistic.16 For calibration, we plotted predicted
risk based on TRS2°P against observed risk in each study and
calculated a modiﬁed Hosmer-Lemeshow v2 statistic.17 We
also calculated the Brier score,18 the average squared
deviation between predicted by TRS2°P and observed event
rates (a lower score represents better calibration). Observed
risk was estimated using the Kaplan–Meier method in each
study.
Since we observed suboptimal calibration in several
cohorts as presented subsequently, we tried to recalibrate
using 2 methods: applying the risk difference between
observed versus predicted in the most prevalent score
category in each cohort to the predicted risk of every patient
(Recalibration 1) and applying the weighted mean risk
difference between observed versus predicted risk across
score categories in each cohort to the predicted risk of every
patient (Recalibration 2).
In RCAV without data on cause of mortality, the Harrell’s
C-statistic and Brier score, which require individual-level
outcome information, were based on the combination of all-
cause mortality, recurrent MI, or ischemic stroke. However,
where individual data were not required, the Hosmer–
Lemeshow v2 statistic was based on 2 scenarios of
cardiovascular death accounting for 50% and 41% of all-
cause death based on the distributions observed in the other
4 cohorts. In 2 cohorts without data on smoking (RCAV and
SCREAM), we simulated the 3-year risk in smokers and
nonsmokers based on reported prevalence and relative risk
of smoking. Details of this hypothetical estimation are
summarized in Figure S1.
To examine variation in discrimination of TRS2°P across
the 5 cohorts, we ﬁrst quantiﬁed the independent association
of the 9 predictors with the risk of MACE. We used Cox
proportional hazards models as done in the original study that
developed TRS2°P.10 Pooled hazard ratios and 95% conﬁ-
dence intervals (CIs) were estimated using a random-effects
meta-analysis. Heterogeneity was evaluated by the v2 test
and the I2 statistic.
For sensitivity analyses, we repeated analyses by stratify-
ing the study sample by sex and race. For race, according to
availability and diversity of racial groups, we only analyzed
whites and blacks in 2 US cohorts (ARIC and RCAV).
All analyses were conducted with the use of Stata
software, version 14.2, and a P value of <0.05 was deemed
statistically signiﬁcant.
Results
Baseline Characteristics
Baseline characteristics of a total of 53 599 patients with
recent MI in each study are shown in Table 1. The median age
of patients with MI ranged from 61 to 72 years across the 5
studies. About 40% were women in ARIC, SCREAM, and
NZDCS, whereas RCAV and KHS had lower proportions of
women (2% and 19%, respectively). Whites made up the
majority among racial groups in all studies except KHS, which
included 100% Asians. There were 26% of patients with black
race in ARIC and 15% in RCAV. The prevalence of heart failure
was lowest in KHS (2%). The prevalence of history of CABG
was 10% in ARIC, RCAV, and NZDCS, but 2% to 3% in
SCREAM and KHS. The prevalence of peripheral artery disease
was strikingly high in RCAV (51% versus ≤13% in the other
cohorts). The prevalence of smoking was highest in KHS
(50%).
The distribution of TRS2°P risk scores among patients with
MI in each cohort is shown in Figure 1. In the 3 studies with
all 9 predictors available, the most prevalent score was 2 in
ARIC and KHS but 3 in NZDCS, which by design only enrolled
individuals with diabetes mellitus. In SCREAM without data on
smoking status, the score 0 to 1 was most prevalent. Despite
the same level of missing data on smoking status, the most
prevalent score was 3 to 4 in RCAV. The prevalence of high-
risk category with TRS2°P ≥310 was the highest in NZDCS
(67%), followed by RCAV (52%), ARIC (40%), and KHS (28%),
and SCREAM (19%).
Descriptive Statistics of MACE
There were 19 444 cases of MACE across 5 studies over a
median follow-up of 1 to 5 years (Table 2). The proportion of
censoring varied from 0% in NZDCS to 24% in KHS. In terms
of the pattern of individual cardiovascular outcomes, recur-
rent MI was consistently more common than ischemic stroke
in all studies, although the degree of difference varied
substantially across the studies. The crude incidence rates of
cardiovascular death and recurrent MI were similar in ARIC
and SCREAM. The crude incidence rate of recurrent MI was
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much higher in RCAV compared with other cohorts (10.5
versus ≤4.0 incidence rate per 100 person-years). As noted,
cardiovascular deaths accounted for 41% to 50% of all deaths
in the 4 studies with available data.
Prediction Statistics
Figure 2 contrasts predicted risk based on ﬁne categories
of TRS2°P and observed risk in each study. Overall, patients
with higher predicted risk of MACE tended to have higher
observed risk in all studies, indicating reasonable risk
discrimination. The C-statistic was highest in SCREAM
(0.685 [95% CI 0.679–0.691]), followed by RCAV (0.631
[0.622–0.639]), NZDCS (0.614 [0.586–0.643]), and ARIC
(0.612 [0.584–0.640]). The C-statistic was lowest in KHS
(0.545 [0.519–571]). The C-statistics in SCREAM and RCAV
were comparable with the original C-statistic in the TRS2°P
derived data set of 0.67.10
In terms of calibration, predicted risk by TRS2°P tended to
be lower than the observed risk of MACE (ie, underestimation)
consistently in all 5 cohorts, with particularly evident differ-
ence in SCREAM (Figure 2). Hosmer-Lemeshow v2 indicated a
signiﬁcant difference between the predicted and observed
risks in every study (P<0.001). For RCAV, the alternative
assumption of 41% of all-cause death from cardiovascular
causes demonstrated similar patterns (Figure S1). For KHS,
Table 1. Basic Characteristics of Included Studies
ARIC RCAV SCREAM KHS NZDCS TRA2°P-TIMI50*
Cohort characteristics
Region US US Sweden South Korea New Zealand 32 countries in Europe, America,
Africa, Asia, and Oceania
Database Community-
based
EMR-based EMR-based Health check-up
data
EMR-base for
diabetes mellitus
Clinical trial
MI cases 1711 9090 38 171 2912 1715 8598
Median follow-up, y† 5.2 0.8 3.9 3.4 4.8 2.5
Calendar year 1987–2013 2006–2013 1996–2012 2004–2013 2000–2007 2007–2009
Demographics
Age, y 68 (62, 74) 64 (60, 72) 61 (51, 71) 61 (53, 68) 72 (62, 79) 59 (51, 66)
Female 41% 2% 38% 19% 40% 20%
Race
White 74% 81% 100% 0% 65% 88%
Black 26% 15% 0% 0% 0% NA
Asian 0.2% 0.2% 0% 100% 6% NA
Others 0% 4% 0% 0% 29% NA
TRS2°P predictors
Heart failure 17% 43% 26% 2% 5% 9%
Hypertension 75% 94% 44% 75% 93% 63%
Age (75 y+) 23% 19% 15% 22% 40% 8%
Diabetes mellitus 39% 61% 19% 31% 100% 22%
Stroke 8% 11% 9% 8% 2% 3%
CABG 10% 9% 2% 3% 7% 14%
Peripheral artery disease 11% 51% 6% 3% 13% 13%
Kidney dysfunction‡ 33% 39% 15% 6% 28% 12%
Current smoking 11% NA NA 50% 16% 20%
Continuous variable presented as median (interquartile range). ARIC indicates Atherosclerosis Risk in Communities; CABG, coronary artery bypass grafting; eGFR, estimated glomerular
ﬁltration rate; EMR, electronic medical record; ICD, International Classiﬁcation of Diseases; KHS, Korean Heart Study; MI, myocardial infarction; NA, not available; NZDCS, New Zealand
Diabetes Cohort Study; RCAV, Racial and Cardiovascular Risk Anomalies in CKD Cohort; SCREAM, Stockholm Creatinine Measurements Cohort; TRA2°P-TIMI50, Thrombin Receptor
Antagonist in Secondary Prevention of Atherothrombotic Ischemic Event-TIMI 50.
*Basic characteristics were derived from TRA2°P-TIMI 50 study that has been reported.10 Races other than White are not available.
†Follow-up after incident MI.
‡Kidney dysfunction: eGFR <60 mL/min per 1.73 m2 or chronic kidney disease based on ICD codes.
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the difference between the predicted and observed risks were
evident at the score <3 and ≥6. The Brier score, which is an
overall performance measure, was 0.144 to 0.173 across 5
studies, while the original Brier score for TRS2°P in its derived
data set was 0.098.10 Both recalibration approaches
substantially improved the calibration of TRS2°P in most
cohorts (Figure S2), with calibration v2 statistics <50 in ARIC,
RCAV, KHS, and NZDCS.
When we analyzed men and women separately, we
observed largely similar results for both sexes within each
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Figure 1. Distribution (%) of the TRS2°P risk score in the 5 cohorts. RCAV and SCREAM do not have smoking data. ARIC indicates
Atherosclerosis Risk in Communities Study; KHS, Korean Heart Study; NZDCS, New Zealand Diabetes Cohort Study; RCAV, Racial and
Cardiovascular Risk Anomalies in CKD Cohort; SCREAM, Stockholm Creatinine Measurements Cohort; TRA2°P-TIMI50, Thrombin Receptor
Antagonist in Secondary Prevention of Atherothrombotic Ischemic Event-TIMI50.
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cohort (Figure S3). For racial groups in 2 US cohorts, risk
discrimination was similar in whites and blacks in both
cohorts (Figure S4). For calibration, the difference between
observed versus predicted risk appeared greater in blacks
than whites in ARIC (Brier score 0.231 versus 0.147).
However, such a racial difference was not observed in
RCAV.
When we simulated current smoking status in SCREAM
and RCAV under the assumption of current smoking preva-
lence rates of 29% for SCREAM19 and 45% for RCAV20 and a
hazard ratio of 1.47,10 the calibration plots were similar to the
primary analysis (which did not account for smoking status)
except for the score ≥7 in SCREAM (Figure S5). The variation
of these assumptions inﬂuenced estimated risk by not >10%
in general (Table S1).
Figure 3 shows 3-year risk estimates of MACE by the
broader categories of TRS2°P corresponding to low, interme-
diate, and high risk (0, 1–2, and ≥3, respectively) proposed in
the original TRS2°P article.10 In every cohort, overall, higher
TRS2°P (particularly ≥3) was consistently associated with
higher risk of MACE, with risk gradient of 3- to 5-fold between
low- and high-risk categories in ARIC, RCAV, and SCREAM.
NZDCS demonstrated a 2-fold risk gradient between high
versus intermediate risk, which is similar to the aforemen-
tioned 3 studies. KHS demonstrated the least separation of
risk among the 3 risk categories based on TRS2°P.
Table 2. Number of Cardiovascular Outcomes and Follow-Up Time
ARIC (N=1711) RCAV (N=9090) SCREAM (N=38 171) KHS (N=2912) NZDCS (N=1715)
MACE*
Cases 762 4853 12 702 586 541
Follow-up, y 5.2 (1.4, 11.0) 0.8 (0.3, 3.4) 3.9 (1.3, 7.5) 3.4 (0.9, 6.6) 4.8 (1.5, 7.9)
Crude IR (per 100 PYs) 6.5 18.4 6.9 5.0 6.5
Cumulative incidence at 3 y 23.1% 43.1% 22.2% 18.9% 21.0%
Censoring other than deaths within 3 y 7.1% 15.5% 15.1% 24.4% 0%
Cardiovascular death
Cases 433 NA 6142 134 198
Follow-up, y 7.6 (2.7, 13.6) NA 5.1 (2.2, 8.8) 4.5 (1.7, 7.3) 6.3 (2.2, 8.4)
Crude IR (per 100 PYs) 2.9 NA 2.8 1.0 2.1
Cumulative incidence at 3 y 10.1% NA 8.3% 3.4% 8.0%
Recurrent MI
Cases 442 2794 6991 468 292
Follow-up, y 5.7 (1.6, 11.4) 0.9 (0.0, 3.5) 4.2 (1.5, 7.9) 3.4 (0.9, 6.6) 5.2 (1.7, 8.0)
Crude IR (per 100 PYs) 3.6 10.5 3.6 4.0 3.4
Cumulative incidence at 3 y 14.3% 28.5% 13.4% 16.3% 10.7%
Ischemic stroke
Cases 149 282 3482 33 154
Follow-up, y 6.8 (2.2, 12.7) 2.7 (0.8, 5.0) 4.8 (1.9, 8.4) 4.5 (1.7, 7.3) 5.8 (2.0, 8.3)
Crude IR (per 100 PYs) 1.1 0.9 1.7 0.2 1.7
Cumulative incidence at 3 y 4.3% 2.4% 5.5% 0.6% 5.7%
All-cause death
Cases 974 3128 15 123 320 1029
Follow-up, y 7.6 (2.7, 13.6) 2.8 (0.9, 5.2) 5.1 (2.2, 8.8) 4.5 (1.7, 7.3) 6.3 (2.2, 8.4)
Crude IR (per 100 PYs) 6.6 9.3 6.9 2.3 11.0
Cumulative incidence at 3 y 20.2% 23.8% 17.4% 8.0% 31.1%
Follow-up presented as median (interquartile range). ARIC indicates Atherosclerosis Risk in Communities; IR, incidence rate; KHS, Korean Heart Study; MACE, major adverse cardiovascular
event; MI, myocardial infarction; NA, not available; NZDCS, New Zealand Diabetes Cohort Study; PYs, person-years; RCAV, Racial and Cardiovascular Risk Anomalies in CKD Cohort;
SCREAM, Stockholm Creatinine Measurements Cohort; TRA2°P-TIMI50, Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Event-TIMI50.
*MACE was deﬁned as cardiovascular death, recurrent MI, and ischemic stroke. RCAV does not have cardiovascular death data, so all-cause death is reﬂected.
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TRA2˚P-TIMI50 for reference
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Figure 2. Three-year probability of major adverse cardiovascular event (MACE) by the TRS2°P. For RCAV,
cardiovascular death was assumed to be 50% of all-cause death because of lack of information on cardiovascular
death, but the C-statistic is not reﬂected. All NZDCS participants had a diagnosis of diabetes mellitus according to their
primary care provider. The 9 risk predictors are heart failure, hypertension, age (≥75 y), diabetes mellitus, stroke,
coronary bypass graft surgery, peripheral artery disease, kidney dysfunction, and smoking. ARIC indicates
Atherosclerosis Risk in Communities Study; KHS, Korean Heart Study; NZDCS, New Zealand Diabetes Cohort Study;
RCAV, Racial and Cardiovascular Risk Anomalies in CKD Cohort; SCREAM, Stockholm Creatinine Measurements Cohort;
TRA2°P-TIMI50, Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Event-TIMI50.
DOI: 10.1161/JAHA.117.008426 Journal of the American Heart Association 7
Atherothrombotic Risk After Myocardial Infarction Mok et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on May 19, 2019
Relative Risk of MACE for Individual Predictors
Across 5 Studies
When we looked at the hazard ratio of MACE for each of the 9
predictors, age ≥75 years was the only risk factor signiﬁ-
cantly associated with MACE in every cohort, with the highest
meta-analyzed hazard ratio of 1.68 (95% CI, 1.25–2.26)
(Table 3). History of heart failure and stroke showed similar
meta-analyzed hazard ratios (1.67 [1.50–1.85] and 1.62
[1.36–1.92], respectively), although they did not reach
statistical signiﬁcance in NZDCS. Peripheral artery disease,
hypertension, diabetes mellitus, and kidney dysfunction had
signiﬁcant associations, with slightly smaller meta-analyzed
hazard ratios of 1.3 to 1.4 compared with the aforementioned
3 potent risk factors. Prior CABG demonstrated signiﬁcantly
positive associations with MACE in ARIC, SCREAM, and
NZDCS, but its meta-analyzed hazard ratios were 1.1 and
did not reach statistical signiﬁcance. Current smoking was not
signiﬁcantly associated with MACE in any of the 3 studies
with available data. I2 statistic indicated high heterogeneity
for age, stroke, CABG, kidney dysfunction, and current
smoking, but a majority of cohorts demonstrated qualitatively
consistent associations even for these risk factors (Figure S6).
Discussion
We evaluated the predictive performance of TRS2°P, a simple
scoring system with 9 routine clinical factors predicting 3-year
prognosis after recent MI, in 5 cohorts outside of a clinical
trial setting from 4 countries with different demographic and
clinical characteristics, and subsequently different adverse
outcome event rates. Our cohorts tended to have higher
scores than the original TRA2°P–TIMI50 population.10 Despite
these demographic and clinical variations, we conﬁrmed that
higher TRS2°P was consistently associated with higher risk of
MACE, indicating reasonable risk discrimination, with
C-statistics ranging from 0.60 to 0.69 in most studies, which
are comparable with those originally reported in the derivation
data set of TRS2°P. Although we recognized a few caveats of
underestimation of absolute risk of MACE by TRS2°P in all 5
cohorts and suboptimal discrimination in a South Korean
study, TRS2°P demonstrated decent risk prediction among
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Figure 3. Three-year risk for major adverse cardiovascular event (MACE) by categories based on TRS2°P
(0 point=low 1–2=intermediate ≥3=high). For RCAV, cardiovascular death was assumed to be 50% of all-
cause death because of lack of information on cardiovascular death. The NZDCS cohort participants all
have diabetes mellitus and thus none are considered low risk. The 9 risk predictors are heart failure,
hypertension, age (≥75 y), diabetes mellitus, stroke, coronary bypass graft surgery, peripheral artery
disease, kidney dysfunction, and smoking. ARIC indicates Atherosclerosis Risk in Communities Study; MI,
myocardial infarction; KHS, Korean Heart Study; NZDCS, New Zealand Diabetes Cohort Study; RCAV, Racial
and Cardiovascular Risk Anomalies in CKD Cohort; SCREAM, Stockholm Creatinine Measurements Cohort;
TRA2°P-TIMI50, Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Event-TIMI50.
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patients with MI in diverse clinical and regional settings. Of
the 9 predictors, our meta-analysis conﬁrmed 7 (heart failure,
hypertension, age ≥75 years, diabetes mellitus, stroke,
peripheral artery disease, and kidney dysfunction) as signif-
icant risk factors; we did not ﬁnd signiﬁcant risk associated
with current smoking and CABG overall.
The most common scores in our cohorts were either 2 or 3,
whereas a score of 1 was most prevalent in the original
TRA2°P–TIMI50.10 We observed higher TRS2°P scores in our
cohorts, despite the lack of smoking information in 2 cohorts.
Our observation may not be surprising since clinical trials
often enroll selected healthier populations because of strin-
gent inclusion and exclusion criteria.21 Indeed, compared with
patients in TRA2°P–TIMI50, participants in our 5 cohorts were
older and more likely to have comorbidities (eg, much higher
prevalence of peripheral artery disease in RCAV and current
smoking in KHS).
The difference in characteristics between our cohorts and
TRA2°P–TIMI50 may be important in explaining why TRS2°P
tended to underestimate the risk of an adverse outcome in
our cohorts. For example, RCAV in our study had a higher
prevalence of comorbidities, as noted above, as well as higher
incidence of cardiovascular outcomes than TRA2°P–TIMI50.10
Indeed, when clinical trials were investigated, TRS2°P demon-
strated good calibration for secondary adverse outcome.22
Also, we should keep in mind that TRA2°P–TIMI50 used
adjudicated outcomes, whereas some of our cohorts relied on
discharge diagnosis to identify MACE. Nonetheless, the Brier
score, a measure of overall model performance, ranged from
0.144 to 0.173 across 5 studies, while the Brier score in the
TRA2°P–TIMI50 was 0.098.10 Although we should keep in
mind the tendency of underestimation in real-world cohorts,
overall, TRS2°P demonstrated decent risk prediction among
patients with recent MI in international non–clinical trial
settings, despite its simple scoring system.
Since the issue of calibration may be ﬁxable by
recalibration,23 as seen in some of our cohorts, discrimination
ability is essential for risk prediction.24 In our study, the ability
of TRS2°P to discriminate the risk of subsequent cardiovas-
cular outcomes among patients with MI was reasonably good.
Four cohorts from the United States, Sweden, and New
Zealand showed C-statistics around 0.61 to 0.69, which are
largely comparable to the original C-statistic in TRA2°P–
TIMI50 of 0.67.10 This may reﬂect the fact that the relative
risk for a key risk factor is often generally consistent across
different clinical and geographic settings,25,26 since discrim-
ination reﬂects the strength of relative risk relationship.
Therefore, TRS2°P seems particularly useful in stratifying
patients into risk categories (as shown in Figure 3) rather
than predicting the absolute risk of having an adverse
outcome. Nonetheless, unlike primary prevention therapy
(eg, statin therapy in 10-year risk of incident atherosclerotic
cardiovascular disease ≥7.5%),27 to our knowledge, there are
no established long-term risk thresholds inﬂuencing sec-
ondary prevention therapy among patients with MI. Thus,
once such a threshold is established for some speciﬁc
treatments in the future among MI patients, TRS2°P should be
tested in the context of that speciﬁc threshold.
Table 3. Multivariable Risk Stratiﬁcation Model for MACE
9 Predictors
ARIC (N=1711) RCAV* (N=9090) SCREAM (N=38 171) KHS (N=2912) NZDCS† (N=1715) Pooled‡ (N=53 599)
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Heart failure 1.94 (1.62–2.33)§ 1.51 (1.38–1.66)§ 1.73 (1.67–1.80)§ 1.71 (1.09–2.70)§ 1.29 (0.86–1.95) 1.67 (1.50–1.85)§
Hypertension 1.30 (1.09–1.54)§ 1.23 (1.06–1.43)§ 1.25 (1.21–1.30)§ 1.13 (0.92–1.38) 1.18 (0.81–1.70) 1.25 (1.21–1.29)§
Age (≥75 y) 1.32 (1.08–1.62)§ 1.41 (1.28–1.56)§ 2.40 (2.29–2.51)§ 1.44 (1.18–1.76)§ 1.99 (1.67–2.38)§ 1.68 (1.25–2.26)§
Diabetes mellitus 1.54 (1.33–1.79)§ 1.26 (1.17–1.37)§ 1.28 (1.23–1.34)§ 1.09 (0.91–1.30)  1.29 (1.19–1.40)§
Stroke 1.69 (1.32–2.16)§ 1.42 (1.25–1.62)§ 1.86 (1.76–1.96)§ 1.72 (1.34–2.21)§ 0.69 (0.29–1.67) 1.62 (1.36–1.92)§
CABG 1.42 (1.14–1.78)§ 0.87 (0.80–0.95) 1.14 (1.02–1.27)§ 0.86 (0.51–1.44) 1.56 (1.17–2.10)§ 1.15 (0.92–1.43)
Peripheral artery disease 1.34 (1.08–1.67)§ 1.34 (1.24–1.46)§ 1.55 (1.46–1.65)§ 1.34 (0.88–2.05) 1.34 (1.04–1.71)§ 1.42 (1.29–1.56)§
Kidney dysfunction 0.90 (0.77–1.06) 1.34 (1.24–1.46)§ 1.71 (1.63–1.80)§ 1.26 (0.92–1.74) 1.47 (1.22–1.77)§ 1.32 (1.06–1.64)§
Current smokingk 0.91 (0.73–1.14) NA NA 1.14 (0.96–1.35) 1.03 (0.81–1.32) 1.04 (0.91–1.19)
All predictors listed in table were included in a Cox proportional hazards model estimating the association between TRS2°P components and composite cardiovascular death, myocardial
infarction, or ischemic stroke. ARIC indicates Atherosclerosis Risk in Communities; CABG, coronary artery bypass graft; CI, conﬁdence interval; HR, hazard ratio; KHS, Korean Heart Study;
MACE, major adverse cardiovascular event; NA, not available; NZDCS, New Zealand Diabetes Cohort Study; RCAV, Racial and Cardiovascular Risk Anomalies in CKD Cohort; SCREAM,
Stockholm Creatinine Measurements Cohort; TRA2°P-TIMI50, Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Event-TIMI50.
*RCAV does not have cardiovascular death data, so all cause is reﬂected.
†All NZDCS participants had a diagnosis of diabetes mellitus according to their primary care provider.
‡Estimated using a random effects meta-analysis.
§P-value <0.05.
kRCAV and SCREAM do not have smoking data.
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The suboptimal discrimination of TRS2°P in a Korean
cohort in our study may deserve some discussion. The low
prevalence of heart failure, one of the strongest predictor in
TRS2°P, might be related to this observation. Regarding the
lack of association between diabetes mellitus and MACE in
our Korean cohort, a previous study from the Korean MI
registry showed similar results from our Korean cohort and
indicates a potentially unique risk factor proﬁle in Korean
patients with MI.28 In addition, a relatively high proportion of
censoring within 3 years in this cohort might play a role as
well. Also, it seems worth recognizing that TRA2°P–TIMI50 did
not include patients from Korea, although it included some
patients from other East Asian countries such as Japan and
China. Nonetheless, future investigations are warranted
because it is critical to develop or validate prediction models
for post-MI patients in Asia.
In terms of each of the 9 predictors in TRS2°P, the meta-
analyzed hazard ratio in our study was similar to the hazard
ratio in TRA2°P-TIMI50 for the following 7 risk factors: heart
failure, hypertension, age, diabetes mellitus, stroke, peripheral
artery disease, and kidney dysfunction. These clinical and
demographic factors have been recognized as important risk
factors among patients with MI in clinical guidelines.29
Moreover, these risk factors are incorporated in a number
of risk prediction models for patients with MI.6,7,28,30–34
In contrast, current smoking and CABG were not evidently
associated with adverse outcomes after MI in our meta-
analysis. For current smoking, interestingly, a few studies
reported that their presence (together with other traditional
atherosclerotic risk factors such as dyslipidemia) was coun-
terintuitively associated with better prognosis among patients
with MI.35–37 Although the exact reasons are not clear,
investigators from those studies made several speculations.
For example, there may be misclassiﬁcation of those factors
after MI. Speciﬁcally, patients with cardiovascular disease
may incorrectly self-report smoking status since they are
under the pressure to quit smoking.38 For CABG, several trials
have shown its survival beneﬁts compared with percutaneous
revascularization or medical treatments in patients with
severe coronary heart disease.39–41 Thus, the prognostic
value of CABG may depend on patient characteristics. Also, it
is noteworthy that prior CABG was signiﬁcantly associated
with increased risk of MACE in 3 out of 5 cohorts.
Our study has several clinical implications. First, TRS2°P
seems generally useful to classify 3-year risk among patients
with recent MI in a broad range of clinical settings. Although
there are a few validated risk stratiﬁcation tools (eg, GRACE
score and TIMI risk score) for patients with acute coronary
syndrome,30,31 most of these mainly aim to predict short-term
risk (eg, in-hospital or 14-day) to make the decision of urgent
revascularization.42,43 Therefore, if the goal is to estimate
longer-term risk over a few years, TRS2°P would be a
reasonable option. While more complex models (eg, equation-
based models including alternative parameterization of
TRS2°P predictors44 or dynamic models using time-varying
electronic health records45) would outperform TRS2°P for
accurately predicting the risk, its simple scoring system will
help healthcare providers easily acknowledge the risk of
patients based on patients’ clinical conditions without using a
computer-based risk calculator. This simple scoring system
may be used even in low resource settings, although this
concept should be tested in low resource settings since our 5
cohorts are from high-income countries.
Second, since TRS2°P tended to underestimate the risk of
adverse outcomes in our setting, in case a more precise
absolute risk estimate is needed for clinical decisions, some
kind of recalibration, as we demonstrated, may be needed for
personalized clinical decisions. Finally, TRS2°P demonstrated
decent risk prediction even among studies without data on
smoking. Although it is deﬁnitely important for healthcare
providers to assess smoking status in daily clinical practice,
data availability of smoking status in clinical database studies
has been challenging.46,47 In this context, our results suggest
that TRS2°P without smoking data may still be useful to
identify high-risk patients with recent MI to be targeted for
research or health promotion.
Our study has several limitations. First, although we did our
best to standardize variable deﬁnitions across cohorts, hetero-
geneity still remained, as noted above. Speciﬁcally, some
cohorts lacked information on smoking status and cardiovas-
cular death. From another point of view, decent prediction
performance of TRS2°P in most studies despite this limitation
seems to indicate its potential generalizability in broad settings.
Second, measurement of the 9 predictors and ascertainment of
outcomes were not necessarily standardized in all cohorts.
Third, black patients in this analysis were only from the 2 US
cohorts, so generalizing to diverse populations should be done
with caution. Fourth, information on ST-elevation versus non-
ST–elevation MI was not available in every cohort, and thus
whether the performance of TRS2°P differs in these 2 types of
MI is yet to be investigated. Nonetheless, TRS2°P was
developed from data without differentiating MI types. Finally,
since we were limited with only 1 or 2 cohorts from a country or
region, we cannot differentiate study-speciﬁc versus country/
region-speciﬁc results related to local practice.
In conclusion, TRS2°P reasonably predicted secondary
events among patients with recent MI in international non–
clinical trial settings, with some caveats to be explored in
future studies (eg, general underestimation of the risk of
adverse outcomes and suboptimal discrimination in a Korean
cohort). Particularly given its simple feature of a 0 to 9 scoring
system with routinely collected variables, TRS2°P may be
considered for classifying the prognosis and to guide risk-
centered management among patients with recent MI.
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Data S1. 
Data analysis overview and analytic notes for some of individual studies 
 
Overview 
As previously described,1 the collaborating cohorts were asked to prepare a dataset with approximately 20 
variables (follow-up time, event variable, nine predictors, and medication uses). To minimize heterogeneity, 
the CKD-PC Data Coordinating Center sent definitions of variables and dataset preparation. We instructed 
studies not to impute any variables.  
 
For 3 of the 5 cohorts in this study,2, 3 the Data Coordinating Center at Johns Hopkins University conducted 
analysis; the remainder ran the standard code written in STATA by the Data Coordinating Center and shared 
the output with the Data Coordinating Center. Standard code was designed to automatically save all output 
including categorical/continuous analyses and survival analyses.   
 
As detailed in our previous report,2, 3 each cohort was instructed to standardize their serum creatinine and 
report its method when available. The reported creatinine standardization allows grouping studies into 
studies that reported using a standard IDMS traceable method or conducted some serum creatinine 
standardization to IDMS traceable methods (ARIC, RCAV, SCREAM) and studies where the creatinine 
standardization was not done (KHS, NZDCS). For those cohorts without standardization, the creatinine 
levels were reduced by 5%, the calibration factor used to adjust non-standardized MDRD Study samples to 
IDMS.2, 4 
 
We calculated eGFR using the CKD-EPI equation5: eGFR = 141 × (minimum of standardized serum 
creatinine [mg/dL]/κ or 1)α × (maximum of standardized serum creatinine [mg/dL]/κ or 1)-1.209 × 0.993age × 
(1.018 if female) × (1.159 if black), where κ is 0.7 if female and 0.9 if male and α is -0.329 if female and -
0.411 if male. Smoking status and eGFR were identified within 1 year prior to incident MI and if not, they 
were missing. To update information on kidney dysfunction, we defined chronic kidney disease based on 
ICD codes. 
 
Notes for individual parent studies (Note: only incident MI cases during follow-up from these studies 
were analyzed for this study) 
ARIC: This cohort is a community-based cohort of participants middle-aged men and women (45-64 years 
old) at baseline 1987-1989. Study participants were predominantly whites and blacks and were recruited 
from 4 US communities: Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, 
Minnesota; and Washington County, Maryland. 
RCAV: US veterans with serum creatinine measurements performed from October 1, 2004, to September 
30, 2006, were identified from the national Veterans Affairs (VA) Corporate Data Warehouse LabChem 
data files. Veterans had at least 1 available serum creatinine measurement, representing ~94% of all veterans 
who received VA health care during this time period. This cohort has very low rates of female (<6%) and 
race other than black or white (<4%). This cohort does not have data on smoking and cause of death. 
SCREAM: This cohort is a health care use cohort from the sole health care provider of the region of 
Stockholm, Sweden. All Stockholm residents aged 18 years or older with data on serum creatinine in either 
inpatient or outpatient care from 2006 to 2011 were included. Given serum creatinine as a common test in 
healthcare, ~66% of the adult population in Stockholm were covered. This cohort does not have data on 
smoking. 
KHS: This cohort included individuals who had voluntarily undergone a health checkup in 18 centers 
located in the capital, Seoul, and 6 provinces in South Korea in 1996 to 2004. Educational attainment and 
socioeconomic status were higher in this cohort relative to overall Korean population. 
NZDCS: This study included participants with a diagnosis of diabetes and no known previous 
cardiovascular event at baseline according to primary care provider in New Zealand. Almost all data were 
collected by 26 organizations around country, all of whom were invited to provide data for this study. 
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Cohort specific definition of recent myocardial infarction (MI) 
Cohort Definition of recent MI 
ARIC Definite and probable MI cases adjudicated by ARIC physician panel 
RCAV Defined as if MI related hospitalization ICD-9 code 410 
SCREAM Defined as if MI related hospitalization ICD-10 code I21 
KHS Defined as if MI related hospitalization ICD-10 code I21 
NZDCS Defined as if MI related hospitalization ICD-9 code 410 
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Cohort specific definition of nine predictors 
Cohort HF HTN Age DM Stroke CABG PAD Kidney 
dysfunction 
Current 
smoking 
ARIC ICD-9 
428 or 
ICD-
10 I50 
BP (≥140/90 
mmHg) or self-
reported doctor 
diagnosed HTN 
At 
MI  
Fasting 
glucose 
≥126 
mg/dL, 
non-fasting 
glucose 
≥200 
mg/dL, 
self-
reported 
doctor 
diagnosed 
diabetes, or 
medication 
Definite 
or 
probable 
strokes 
were 
identified 
by 
computer 
algorithm 
and 
review 
by a 
physician 
ICD-9 36.1 ICD-9 440.2 440.3 
440.4 443.9 707.1 
785.4 38.18 39.25 
39.29 39.50 84.1 
eGFR<60 
ml/min/1.73m2 
within 1 year 
prior to MI or 
CKD based on 
ICD codes 
Within 
1 year 
prior to 
MI 
RCAV ICD-9 
428 
ICD-9 401-405 At 
MI 
ICD-9 250* ICD-9 
430 431 
432 
433.*1 
434.*1 
CPT 33510 -
33519 33521-
33523 33533-
33536 
ICD-9 codes 
440.X, leg 
revascularization, 
leg amputation 
eGFR<60 
ml/min/1.73m2 
within 1 year 
prior to MI or 
CKD based on 
ICD codes 
NA 
SCREAM ICD-
10 I50 
ICD-10 I10-I15 At 
MI 
ICD-10 
E10 E11 
E13 
ICD-10 
I61-I63 
NOMESCO 
classification FN 
FNA FNB FNC 
FND FNE 
ICD-10 I70.2x or 
I70.92, leg 
revascularization, 
leg amputation  
eGFR<60 
ml/min/1.73m2 
within 1 year 
prior to MI or 
CKD based on 
ICD codes 
NA 
KHS ICD-
10 I50 
BP (≥140/90 
mmHg), self-
reported doctor 
diagnosed HTN 
or medication 
history or ICD-10 
I10-I15 
At 
MI 
Fasting 
glucose 
≥126 
mg/dL, 
self-
reported 
doctor 
diagnosed 
diabetes or 
medication 
history or 
ICD-10 
E10 E11 
E13 
ICD-10 
I61-I69 
ICD-10 I20-I25 
Z95.1 Z98.61, 
leg 
revascularization 
ICD-10 I70.0I70.1 
I70.2 I70.8 I72.4 
I73.1 I73.8 I73.9 
I74.2 I74.3 I74.4 
I74.5 I96 E11.5 
E12.5 E13.5 E14.5 
eGFR<60 
ml/min/1.73m2 
within 1 year 
prior to MI or 
CKD based on 
ICD codes 
Within 
1 year 
prior to 
MI 
NZDCS ICD-9 
40201, 
40211, 
40291, 
40401, 
40403, 
40411, 
40413, 
40491, 
40493, 
4280, 
4281, 
4289, 
4282, 
4284 
 
ICD-
10 
I110, 
I130, 
I132, 
I50, 
J81 
BP (≥140/90 
mmHg), on 
antihypertensives/ 
ACEI 
At 
MI 
Doctor 
diagnosed 
diabetes or 
medication 
history or 
Glycated 
hemoglobin 
A1c ≥6.5% 
ICD-9 
431, 
4329, 
43401, 
43411, 
43491, 
438 
 or ICD-
10 I61, 
I630, 
I631, 
I632, 
I633, 
I634, 
I635, 
I637, 
I638, 
I639, I64, 
I693, 
I690, 
I691, 
I692, 
I694, 
I698 
ICD-9 V4581 or 
ICD-10 Z951 
ICD-9 25073, 380, 
381, 3840, 3841, 
3842, 3843, 3844, 
3845, 3846, 3848, 
3849, 3922, 3924, 
3925, 3926, 3928, 
3929, 44021, 
44022, 44023, 
44024 or ICD-10 
E1051, E1052, 
E1151, E1152, 
E1451, E1452, 
I7021, I7022, 
I7023, I7024, 
273300, 327000, 
327630, 327631, 
3270010, 3270011, 
3270300, 3270800, 
3270801, 3270802, 
3270803, 3271200, 
3271201, 3271500, 
3271501','3271502, 
3271503, 3271800, 
3271801, 3273000, 
3273001, 3273301, 
3273600, 3273900, 
3274200, 3274500, 
3274800, 32751, 
3275200, 3275201, 
3275202, 3275203, 
3275400, 3275401, 
3275402, 3275700, 
eGFR<60 
ml/min/1.73m2 
within 1 year 
prior to MI or 
CKD based on 
ICD-9 codes 
2504, 582, 
583, 5853, 
5854, 5855, 
5856, 586, 
587, 588, 
5939, 403, 
404, V420 or 
ICD-10 codes 
E1021, E1029, 
E1065, E1121, 
E1129, E1165, 
I120, I129, 
I130, I131, 
I132, N032, 
N033, N035, 
N038, N039, 
N052, N055, 
N058, N059, 
N08, N171, 
N172, N183, 
N184, N185, 
N186, N19, 
N250, N251, 
N258, N259, 
N269, N289, 
Z940 
Within 
1 year 
prior to 
MI 
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3275701, 3530306, 
3530307, 3530906, 
3530907, 3530908, 
3530909, 3350000, 
3350600, 3350601, 
3350900, 3351200, 
3351500, 3351501, 
3351800, 3352100, 
3352400, 3352700, 
3353000, 3353001, 
3353300, 3353600 
Abbreviations: BP, blood pressure; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CPT, Current Procedure 
Terminology; DM, diabetes; eGFR, estimated glomerular filtration rate; HF, heart failure; HTN, hypertension; ICD, International 
Classification of Diseases; MI, myocardial infarction; NOMESCO, Nordic Medico-Statistical Committee; PAD, peripheral artery 
disease 
 
Exclusion criteria 
ARIC: 1,795 participants developed incident MI during follow-up. We excluded 45 participants who did not 
have complete information on nine predictors in TRS2°P and 39 participants who died within 14 days after 
incident MI, leaving a sample of 1,711 participants. 
 
RCAV: 10,720 participants developed incident MI during follow-up. We excluded 511 participants who 
died within 14 days after incident MI. Of these participants, we included those who had any outpatient visits 
after incident MI, leaving a sample of 9,090 participants. 
 
SCREAM: 41,247 participants developed incident MI during follow-up. We excluded 603 participants who 
did not have complete information on nine predictors in TRS2°P and 2,473 participants who died within 14 
days after incident MI, leaving a sample of 38,171 participants. 
 
KHS: 3,043 participants developed incident MI during follow-up. We excluded 13 participants who did not 
have complete information on nine predictors in TRS2°P and 118 participants who died within 14 days after 
incident MI, leaving a sample of 2,912 participants. 
 
NZDCS: 4,914 participants developed incident MI during follow-up (2000 to 2007). Then we excluded 
2,738 participants who did not have complete information on nine predictors in TRS2°P and 461 
participants who died within 14 days after incident MI, leaving a sample of 1,715 participants. 
 
 
 
 
 
 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on May 19, 2019
  
Data S2.  
Acronyms or abbreviations for studies included in the current report and their key references linked 
to the Web references 
 
ARIC: Atherosclerosis Risk in Communities Study6 
RCAV: Racial and Cardiovascular Risk Anomalies in CKD Cohort7 
SCREAM: Stockholm CREAtinine Measurements Cohort8 
KHS: Korean Heart Study9 
NZDCS: New Zealand Diabetes Cohort Study10 
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Data S3.  
Acknowledgements and funding for collaborating cohorts 
 
Study List of sponsors 
ARIC The Atherosclerosis Risk in Communities study has been funded in whole or in part with 
Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of 
Health, Department of Health and Human Services, under Contract nos. 
(HHSN268201700001I, HHSN268201700003I, HHSN268201700005I, 
HHSN268201700004I, HHSN2682017000021). The authors thank the staff and 
participants of the ARIC study for their important contributions. 
RCAV This study was supported by grant R01DK096920 from NIH-NIDDK and is the result of 
work supported with resources and the use of facilities at the Memphis VA Medical 
Center and the Long Beach VA Medical Center. Support for VA/CMS data is provided 
by the Department of Veterans Affairs, Veterans Health Administration, Office of 
Research and Development, Health Services Research and Development, VA 
Information Resource Center (project numbers SDR 02-237 and 98-004). 
SCREAM This study was supported by Stockholm County Council and the Swedish Heart and 
Lung Foundation. 
KHS This study was funded by a grant of the Korean Health Technology R&D Project, 
Ministry of Health & Welfare, Republic of Korea HI14C2686 and HI13C0715. 
NZDCS New Zealand Health Research Council, Auckland Medical Research Foundation and 
New Zealand Society for the Study of Diabetes 
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Table S1. Three-year cumulative incidence of hypothetically incorporated smoking status by the 
TRS2˚P risk score in SCREAM and RCAV. 
  TRS2˚P risk score 
HR PRsmk 0 1 2 3 4 5 6 7+ 
SCREAM Not 
accounting 0.0987 0.1674 0.2822 0.4277 0.5505 0.6539 0.7410 0.4668 
1.07 25% 0.0971 0.1490 0.2432 0.3743 0.5042 0.6092 0.6969 0.6733 
 29% 0.0969 0.1462 0.2379 0.3673 0.4982 0.6042 0.6929 0.6813 
 35% 0.0965 0.1419 0.2301 0.3574 0.4899 0.5974 0.6878 0.6904 
1.17 25% 0.0949 0.1481 0.2432 0.3759 0.5081 0.6169 0.7088 0.6895 
 29% 0.0944 0.1452 0.2378 0.3690 0.5024 0.6122 0.7051 0.6974 
 35% 0.0935 0.1408 0.2301 0.3592 0.4943 0.6056 0.6999 0.7058 
1.27 25% 0.0929 0.1472 0.2432 0.3775 0.5118 0.6240 0.7197 0.7041 
 29% 0.0920 0.1442 0.2378 0.3707 0.5063 0.6196 0.7163 0.7118 
 35% 0.0907 0.1398 0.2301 0.3609 0.4983 0.6132 0.7111 0.7198 
1.37 25% 0.0909 0.1464 0.2432 0.3790 0.5153 0.6306 0.7297 0.7171 
 29% 0.0897 0.1433 0.2378 0.3723 0.5099 0.6265 0.7265 0.7248 
 35% 0.0880 0.1388 0.2301 0.3625 0.5021 0.6202 0.7213 0.7325 
1.47 25% 0.0890 0.1456 0.2433 0.3805 0.5186 0.6368 0.7389 0.7289 
 29% 0.0876 0.1424 0.2378 0.3738 0.5134 0.6329 0.7359 0.7366 
 35% 0.0856 0.1379 0.2301 0.3640 0.5056 0.6267 0.7307 0.7440 
1.57 25% 0.0872 0.1448 0.2433 0.3819 0.5218 0.6426 0.7474 0.7395 
 29% 0.0856 0.1416 0.2379 0.3752 0.5167 0.6389 0.7446 0.7473 
 35% 0.0832 0.1370 0.2301 0.3655 0.5090 0.6329 0.7395 0.7545 
          
RCAV Not 
accounting 0.1489 0.1930 0.2529 0.3088 0.4084 0.4512 0.5339 0.6011 
1.07 40% 0.1452 0.1860 0.2339 0.2815 0.3661 0.4317 0.4847 0.5626 
 45% 0.1447 0.1850 0.2312 0.2786 0.3610 0.4296 0.4809 0.5605 
 50% 0.1443 0.1839 0.2285 0.2759 0.3560 0.4275 0.4774 0.5585 
1.17 40% 0.1402 0.1807 0.2309 0.2830 0.3654 0.4341 0.4922 0.5766 
 45% 0.1392 0.1791 0.2280 0.2801 0.3603 0.4319 0.4882 0.5737 
 50% 0.1381 0.1775 0.2251 0.2773 0.3553 0.4298 0.4844 0.5708 
1.27 40% 0.1356 0.1757 0.2280 0.2843 0.3648 0.4363 0.4991 0.5894 
 45% 0.1340 0.1737 0.2250 0.2815 0.3597 0.4341 0.4949 0.5858 
 50% 0.1326 0.1717 0.2220 0.2786 0.3546 0.4319 0.4907 0.5820 
1.37 40% 0.1313 0.1711 0.2253 0.2856 0.3642 0.4383 0.5056 0.6013 
 45% 0.1293 0.1687 0.2222 0.2827 0.3591 0.4361 0.5011 0.5969 
 50% 0.1274 0.1663 0.2192 0.2798 0.3540 0.4338 0.4966 0.5923 
1.47 40% 0.1273 0.1668 0.2229 0.2868 0.3637 0.4402 0.5115 0.6123 
 45% 0.1250 0.1640 0.2197 0.2839 0.3585 0.4380 0.5069 0.6073 
 50% 0.1227 0.1614 0.2166 0.2810 0.3535 0.4356 0.5020 0.6019 
1.57 40% 0.1235 0.1627 0.2205 0.2879 0.3632 0.4419 0.5171 0.6226 
 45% 0.1209 0.1597 0.2173 0.2849 0.3580 0.4397 0.5122 0.6169 
 50% 0.1184 0.1568 0.2142 0.2820 0.3529 0.4373 0.5071 0.6108 
For RCAV, cardiovascular death was assumed to be 50% of all-cause death due to lack of information on 
cardiovascular death. 
Two key elements determining the MACE cumulative incidence within smokers and non-smokers are the prevalence 
of smokers and the relative risk of smokers compared with non-smokers.   
Risknonsmk = CInonsmk+smk / ((PRsmk * (RRsmk -1))+1 ) and Risksmk = (1-(1- Risknonsmk)HR
smk 
Here CInonsmk+smk is observed cumulative incidence of cardiovascular events at a given TRS2°P category not 
accounting for smoking status (in other words, cumulative incidence lumping non-smokers and smokers). PRsmk is the 
prevalence of smokers, and we primarily used the prevalence of smokers (29%) in SWEDEHEART,11 a Swedish 
registry of MI cases, for SCREAM and the prevalence of smokers (45%) among US veterans with coronary heart 
disease 12 for RCAV. RRsmk is relative risk of smokers compared with non-smokers, and we primarily used the hazard 
ratio of 1.47 in the derived dataset of TRS2°P (TRA 2°P–TIMI50) but also explored other hazard ratios including the 
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one from our meta-analysis shown subsequently.13 We used hazard ratios from TRS2°P and our meta-analysis as 
approximation of relative risk. Cumulative incidence accounting for smoking is a weighted average of MACE 
cumulative incidence in smokers and that in non-smokers. 
 
Figure. Estimating CI of incorporated smoking status 
 
CI, cumulative incidence; HR, hazard ratio; PRsmk, prevalence of current smoking 
PRsmk X Risksmk (1-PRsmk) X RisknonsmkCIsmk+nonsmk
Risknonsmk X (PRsmk X (RRsmk-1) +1)
PRsmk X RRsmk* X Risknonsmk
*RRsmk = Risksmk / Risknonsmk ~ HRsmk
(1-PRsmk) X Risknonsmk
Risknonsmk = CIsmk+nonsmk / (PRsmk X (RRsmk-1) +1)
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Figure S1. Calibration plot for major adverse cardiovascular event (MACE) by categories of TRS2˚P 
risk score in RCAV. 
 
RCAV 
 
  
 
Cardiovascular death was assumed to be 41% of all-cause death due to lack of information on cardiovascular death. 
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Figure S2. Three-year probability of major adverse cardiovascular event (MACE) of recalibrated 
predicted risk and observed risk by the TRS2°P. 
 
ARIC RCAV 
  
Original x2: 273.1, p<0.001 Original x2: 1946.2, p<0.001 
Calibration1 x2: 14.8, p=0.098 Calibration1 x2: 41.0, p<0.001 
Calibration2 x2: 12.1, p=0.205 Calibration2 x2: 37.4, p<0.001 
SCREAM KHS 
  
Original x2: 10,542.6, p<0.001 Original x2: 377.8, p<0.001 
Calibration1 x2: 3,189.8, p<0.001 Calibration1 x2: 29.3, p=0.001 
Calibration2 x2: 1,599.4, p<0.001 Calibration2 x2: 28.2, p=0.001 
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Original x2: 67.3, p<0.001  
Calibration1 x2: 29.7, p<0.001  
Calibration2 x2:20.8, p=0.013  
 
 
 
For RCAV, cardiovascular death was assumed 50% of all-cause death due to lack of information on cardiovascular 
death; All NZDCS participants had a diagnosis of diabetes according to primary care provider. Calibration 1: 
𝑃𝑟𝑒𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 = 𝑃𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 + (𝑂𝑖 − 𝑃𝑖), Calibration 2: 𝑃𝑟𝑒𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑= 𝑃𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙  +  
∑ 𝑓𝑗×(𝑂𝑗−𝑃𝑗)
7
𝑗=0
𝑁
 Where, Precalibrated is 
recalibrated predicted risk at a given TRS2°P category and Poriginal is original predicted risk at a given TRS2°P 
category. Oi is observed risk at the most prevalent score in each cohort, Pi is original predicted risk at the most 
prevalent score in each cohort. fj=f0, f1, f2, …, f7 is frequency corresponding to each TRS2°P category and Oj=O0, O1, 
O2, …, O7 is observed risk corresponding to each category. 
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Figure S3. Three-year probability of major adverse cardiovascular event (MACE) by categories of 
TRS2˚P and sex. 
For RCAV, cardiovascular death was assumed 50% of all-cause death due to lack of information on cardiovascular 
death, but, in number of cases, all-cause reflected; All NZDCS participants had a diagnosis of diabetes according to 
primary care provider. 
Men Women 
ARIC  
  
Cases/N: 442/1,013 Cases/N: 320/698 
x2: 117.4, p<0.001; Brier score: 0.162 x2: 102.2, p<0.001; Brier score: 0.180 
C statistic: 0.631 (0.593-0.669) C statistic: 0.628 (0.587-0.669) 
RCAV  
  
Cases/N: 4,779/8,951 Cases/N: 74/139 
x2: 5,219.6, p<0.001; Brier score: 0.186 x2: 115.1, p<0.001; Brier score: 0.208 
C statistic: 0.617 (0.608-0.626) C statistic: 0.645 (0.571-0.720) 
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Cases/N: 7,099/23,479 Cases/N: 5,603/14,692 
x2: 5097.4, p<0.001; Brier score: 0.148 x2: 5668.2, p<0.001; Brier score: 0.196 
C statistic: 0.683 (0.675-0.691) C statistic: 0.674 (0.666-0.683) 
KHS  
  
Cases/N: 478/2,371 Cases/N: 108/541 
x2: 351.5, p<0.001; Brier score: 0.145 x2: 54.8, p<0.001; Brier score: 0.140 
C statistic: 0.553 (0.524-0.582) C statistic: 0.579 (0.521-0.637) 
NZDCS  
  
Cases/N: 311/1,026 Cases/N: 230/689 
x2: 39.1, p<0.001; Brier score: 0.148 x2: 32.9, p<0.001; Brier score: 0.157 
C statistic: 0.626 (0.588-0.664) C statistic: 0.598 (0.554-0.643) 
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Figure S4. Three-year probability of major adverse cardiovascular event (MACE) by categories of 
TRS2˚P risk score and race in ARIC and RCAV. 
 
White Black 
ARIC  
  
Cases/N: 520/1,260 Cases/N: 241/447 
x2: 90.5, p<0.001; Brier score: 0.147 x2: 166.5, p<0.001; Brier score: 0.231 
C statistic: 0.625 (0.590-0.660) C statistic: 0.622 (0.576-0.668) 
RCAV  
  
Cases/N: 3,898/7,226 Cases/N: 378/1,317 
x2: 4,408.7, p<0.001; Brier score: 0.189 x2: 581.2, p<0.001; Brier score: 0.168 
C statistic: 0.616 (0.606-0.626) C statistic: 0.625 (0.602-0.649) 
 
For RCAV, cardiovascular death was assumed 50% of all-cause death due to lack of information on cardiovascular 
death, but, in number of cases, all-cause reflected. 
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Figure S5. Calibration plot for major adverse cardiovascular event (MACE) according to TRS2˚P in 
SCREAM and RCAV after hypothetically implementing smoking status. 
 
SCREAM RCAV (A) 
  
 RCAV (B) 
 
 
 
 
For SCREAM, the assumed prevalence of current smoking was 29% and the assumed hazard ratio was 1.47. For 
RCAV, the assumed prevalence of current smoking was 45% and the assumed hazard ratio was 1.47. Cardiovascular 
death was assumed to be 50% (A) and 41% (B) of all-cause death due to lack of information on cardiovascular death. 
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Figure S6. Forest plots for major adverse cardiovascular event (MACE) by each of the nine 
predictors. 
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